ライフサイエンスコーパス: pulmonary disease

1 onic kidney disease, and chronic obstructive pulmonary disease).

2 atment for patients with chronic obstructive pulmonary disease.

3 ion, and associated with chronic obstructive pulmonary disease.

4 dification by asthma and chronic obstructive pulmonary disease.

5 herapeutic approaches in chronic obstructive pulmonary disease.

6 th acute exacerbation of chronic obstructive pulmonary disease.

7 lity to NTM infection and its progression to pulmonary disease.

8 ted yet in patients with chronic obstructive pulmonary disease.

9 the main risk factor for chronic obstructive pulmonary disease.

10 raining in patients with chronic obstructive pulmonary disease.

11 cystic fibrosis (CF) and chronic obstructive pulmonary disease.

12 dicate an early stage of chronic obstructive pulmonary disease.

13 cal history of asthma or chronic obstructive pulmonary disease.

14 in patients with severe chronic obstructive pulmonary disease.

15 d cohort free of clinical cardiovascular and pulmonary disease.

16 matory diseases, such as chronic obstructive pulmonary disease.

17 no previous spirometry testing or diagnosed pulmonary disease.

18 y developmental phase of chronic obstructive pulmonary disease.

19 76 men) free of prevalent cardiovascular and pulmonary disease.

20 or in the development of chronic obstructive pulmonary disease.

21 s a syndromic condition including late-onset pulmonary disease.

22 patients suffering from chronic obstructive pulmonary disease.

23 cerbations of asthma and chronic obstructive pulmonary disease.

24 msubsp.hominissuis" is an important cause of pulmonary disease.

25 om cirrhosis, cancer, or chronic obstructive pulmonary disease.

26 mans from zoonotic sources and causes severe pulmonary disease.

27 or agonist used to treat chronic obstructive pulmonary disease.

28 airway diseases, such as chronic obstructive pulmonary disease.

29 both cystic fibrosis and chronic obstructive pulmonary disease.

30 l lung pathologies, e.g. chronic obstructive pulmonary disease.

31 iew the contributions of the inflammasome to pulmonary diseases.

32 the lipidome for future MALDI-MSI studies of pulmonary diseases.

33 marily because of cardiovascular and chronic pulmonary diseases.

34 the effects of therapeutic interventions in pulmonary diseases.

35 velopment, injury, and repair as well as key pulmonary diseases.

36 ired goal in patients with acute and chronic pulmonary diseases.

37 erous human inflammatory diseases, including pulmonary diseases.

38 included diabetes (21%), chronic obstructive pulmonary disease (12%), and immunosuppression (3%).

39 y disease (15.6%-22.3%), chronic obstructive pulmonary disease (14.4%-20.1%), anemia (12.4%-20.4%), c

40 abetes mellitus (29.5%), chronic obstructive pulmonary disease (16.0%), and a mean logistic EuroSCORE

41 e inception of asthma or chronic obstructive pulmonary disease, (2) inflammatory phenotyping, (3) exa

42 ilty (29%), frailty with chronic obstructive pulmonary disease (25%), and frailty with diabetes melli

43 8% versus 12%, P<0.001), chronic obstructive pulmonary disease (5% versus 3%, P=0.004), urgent/emerge

44 ), diabetes (22.3%), and chronic obstructive pulmonary disease (9.4%).

45 evalent diseases such as chronic obstructive pulmonary disease, acquired rhinosinusitis, pancreatitis

46 sing MRI contrast agent for the diagnosis of pulmonary diseases affecting the surface of the respirat

47 mitation compatible with chronic obstructive pulmonary disease affects almost one-third of patients w

48 excessive alcohol, smoking, hyperthyroidism, pulmonary disease, air pollution, and possibly excessive

49 excessive alcohol, smoking, hyperthyroidism, pulmonary disease, air pollution, heart failure, and pos

50 lure, moderate-to-severe chronic obstructive pulmonary disease, airway patency problems, and prolonge

51 tion; moderate to severe chronic obstructive pulmonary disease; airway patency problems; or prolonged

52 c pulmonary fibrosis and chronic obstructive pulmonary disease, although the factors that regulate ea

53 the higher prevalence of chronic obstructive pulmonary disease among Puerto Ricans and Cubans was lar

54 59, 95 % CI: 1.33-1.90), chronic obstructive pulmonary disease and bronchiectasis (HR 1.55, 95 % CI:

55 ic lung disease, such as chronic obstructive pulmonary disease and cystic fibrosis, exhibited increas

56 ex-smokers with combined chronic obstructive pulmonary disease and heart failure with reduced left ve

57 patients with coexistent chronic obstructive pulmonary disease and heart failure.

58 driceps of patients with chronic obstructive pulmonary disease and intensive care unit-acquired weakn

59 varied phenotypically as chronic obstructive pulmonary disease and IPF and suggest that these hubs ma

60 f airflow obstruction in chronic obstructive pulmonary disease and may precede emphysema development.

61 isorders, and history of chronic obstructive pulmonary disease and occupational lung disease.

62 any patients with chronic severe obstructive pulmonary disease and other advanced lung disorders.

63 n central Appalachia for chronic obstructive pulmonary disease and pneumoconiosis; widely dispersed t

64 usceptibility to develop chronic obstructive pulmonary disease and pulmonary function levels, includi

65 eumatoid arthritis, asthma, atherosclerosis, pulmonary diseases and Crohn's disease as hubs and thus

66 , stroke, pneumonia, and chronic obstructive pulmonary disease) and a surgical diagnosis (hip fractur

67 c heart disease, stroke, chronic obstructive pulmonary disease, and cancers (liver, stomach, and lung

68 to rescue were ascites, chronic obstructive pulmonary disease, and diabetes.

69 cerebrovascular disease, chronic obstructive pulmonary disease, and hemoglobin, was a powerful predic

70 emia occurs in advanced hepatic, cardiac and pulmonary disease, and in urea cycle enzyme deficiencies

71 atory distress syndrome, chronic obstructive pulmonary disease, and interstitial lung diseases such a

72 x, polyvascular disease, chronic obstructive pulmonary disease, and malignancy.

73 asthma, 298,751 cases of chronic obstructive pulmonary disease, and more than 1.1 million cases of al

74 rease) with respiratory, chronic obstructive pulmonary disease, and pneumonia mortality, with risk ra

75 seases including asthma, chronic obstructive pulmonary disease, and pulmonary fibrosis.

76 pathogenesis of asthma, chronic obstructive pulmonary disease, and pulmonary infection.

77 participants, those with chronic obstructive pulmonary disease, and those with more than 35 pack-year

78 Models of human RSV pulmonary disease are needed to better understand RSV pa

79 to 45%) of patients with chronic obstructive pulmonary disease are never-smokers, most genetic suscep

80 onary fibrosis (IPF) and chronic obstructive pulmonary disease are usually studied in isolation, and

81 phages (AM) are found in chronic obstructive pulmonary disease, asthma, cystic fibrosis, and adenosin

82 including renal disease, chronic obstructive pulmonary disease, atrial fibrillation, heart disease, a

83 In patients with worsening pulmonary disease awaiting lung transplantation, those s

84 to the ED were more likely to be black, have pulmonary disease, be insured by the Centers for Medicai

85 levated in patients with chronic obstructive pulmonary disease but more markedly in patients with ICU

86 patients with asthma and chronic obstructive pulmonary disease, but are not recommended for those wit

87 rticularly in asthma and chronic obstructive pulmonary disease, but their potential role in patients

88 roke, arthritis, asthma, chronic obstructive pulmonary disease, cancer, weak/failing kidneys, diabete

89 p (atrial septal defect, chronic obstructive pulmonary disease, chest pain, diverticulitis, enteroves

90 with severe/very severe chronic obstructive pulmonary disease, chronic bronchitis, two or more exace

91 Heart Association class, chronic obstructive pulmonary disease, chronic kidney disease, N-terminal-pr

92 cerebrovascular disease, chronic obstructive pulmonary disease, chronic renal failure, previous invas

93 asthma were as follows: chronic obstructive pulmonary disease (COPD) (13.4% vs 3.1%), depression (17

94 Chronic obstructive pulmonary disease (COPD) affects over 65 million individ

95 expression that occur in chronic obstructive pulmonary disease (COPD) after corticosteroid treatment

96 s (ICS) in patients with chronic obstructive pulmonary disease (COPD) and a history of exacerbations.

97 nts, human patients with chronic obstructive pulmonary disease (COPD) and amyotrophic lateral scleros

98 n lungs of patients with chronic obstructive pulmonary disease (COPD) and asthma compared to controls

99 characteristics of both chronic obstructive pulmonary disease (COPD) and asthma, named asthma-COPD o

100 lung diseases including chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), but l

101 Patients with chronic obstructive pulmonary disease (COPD) and in particular smokers are m

102 To determine how chronic obstructive pulmonary disease (COPD) and mechanical ventilation time

103 mulant for patients with chronic obstructive pulmonary disease (COPD) and metabolic alkalosis, but no

104 in patients with stable chronic obstructive pulmonary disease (COPD) and resting or exercise-induced

105 Worldwide, chronic obstructive pulmonary disease (COPD) and stroke are leading causes o

106 Asthma and chronic obstructive pulmonary disease (COPD) are highly prevalent chronic ob

107 t airway inflammation in chronic obstructive pulmonary disease (COPD) are incompletely understood.

108 therapy in patients with chronic obstructive pulmonary disease (COPD) are limited.

109 Patients with chronic obstructive pulmonary disease (COPD) are susceptible to respiratory

110 l lung disease (ILD) and chronic obstructive pulmonary disease (COPD) are unknown.

111 ies comparing asthma and chronic obstructive pulmonary disease (COPD) based on thoracic quantitative

112 ilation in patients with chronic obstructive pulmonary disease (COPD) by using free-breathing dynamic

113 ce for the management of chronic obstructive pulmonary disease (COPD) comes from closely monitored ef

114 Chronic obstructive pulmonary disease (COPD) comprises chronic bronchitis an

115 networks in healthy and chronic obstructive pulmonary disease (COPD) contexts.

116 1 cells in patients with chronic obstructive pulmonary disease (COPD) correlated with disease severit

117 regions have effects on chronic obstructive pulmonary disease (COPD) development, while long noncodi

118 ns and symptoms of acute chronic obstructive pulmonary disease (COPD) exacerbation.

119 hils are associated with chronic obstructive pulmonary disease (COPD) exacerbations among individuals

120 acterial pathogen during chronic obstructive pulmonary disease (COPD) exacerbations and is a plausibl

121 ve ventilation (NIV) for chronic obstructive pulmonary disease (COPD) exacerbations, helium/oxygen (h

122 l industry, and academic chronic obstructive pulmonary disease (COPD) experts with advisors from the

123 RATIONALE: Patients with chronic obstructive pulmonary disease (COPD) frequently have albuminuria (in

124 Since Chronic Obstructive Pulmonary disease (COPD) has emerged as a central hub in

125 atory conditions such as chronic obstructive pulmonary disease (COPD) has not been investigated.

126 therapy by patients with chronic obstructive pulmonary disease (COPD) has not been reported.

127 s in blood and sputum in chronic obstructive pulmonary disease (COPD) have been associated with incre

128 People with advanced chronic obstructive pulmonary disease (COPD) have distressing physical and p

129 havior and lung function/chronic obstructive pulmonary disease (COPD) have not been systematically ex

130 es to infect healthy and chronic obstructive pulmonary disease (COPD) human ciliated respiratory epit

131 deaths among people with chronic obstructive pulmonary disease (COPD) in England and Scotland 2011-20

132 susceptibility gene for chronic obstructive pulmonary disease (COPD) in genome-wide association stud

133 merging as biomarkers of chronic obstructive pulmonary disease (COPD) in individuals exposed to cigar

134 een childhood asthma and chronic obstructive pulmonary disease (COPD) in later life has been demonstr

135 ssociation of asthma and chronic obstructive pulmonary disease (COPD) in the same patient, which is d

136 The burden of chronic obstructive pulmonary disease (COPD) in the USA continues to grow.

137 : Acute exacerbations of chronic obstructive pulmonary disease (COPD) increase the risk of death and

138 RATIONALE: Chronic obstructive pulmonary disease (COPD) is a chronic, progressive disea

139 Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous

140 Chronic obstructive pulmonary disease (COPD) is a condition characterized by

141 Chronic obstructive pulmonary disease (COPD) is a devastating disease with n

142 Chronic obstructive pulmonary disease (COPD) is a leading cause of death wor

143 Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality

144 Chronic obstructive pulmonary disease (COPD) is a risk factor for lung cance

145 Chronic obstructive pulmonary disease (COPD) is associated with chronic infl

146 Chronic obstructive pulmonary disease (COPD) is characterized by chronic air

147 Chronic obstructive pulmonary disease (COPD) is characterized by chronic air

148 Chronic obstructive pulmonary disease (COPD) is characterized by chronic bro

149 RATIONALE: Chronic obstructive pulmonary disease (COPD) is characterized by impaired cl

150 Chronic obstructive pulmonary disease (COPD) is characterized by peribronchi

151 Chronic obstructive pulmonary disease (COPD) is characterized by reduced lun

152 ng to the development of chronic obstructive pulmonary disease (COPD) is crucial for developing new t

153 ONALE: The prevalence of chronic obstructive pulmonary disease (COPD) is increasing faster among wome

154 RATIONALE: The burden of chronic obstructive pulmonary disease (COPD) is increasing, yet there are li

155 tion among patients with chronic obstructive pulmonary disease (COPD) is largely unknown.

156 Chronic obstructive pulmonary disease (COPD) is linked to both cigarette smo

157 RATIONALE: Chronic obstructive pulmonary disease (COPD) is often unrecognized and untre

158 Chronic obstructive pulmonary disease (COPD) is regarded as a disease of acc

159 levance in patients with chronic obstructive pulmonary disease (COPD) is scarce.

160 ingly aging populations, chronic obstructive pulmonary disease (COPD) is the fourth leading cause of

161 ette smoke (CS) -induced chronic obstructive pulmonary disease (COPD) is the primary testing methodol

162 Chronic obstructive pulmonary disease (COPD) is the third leading cause of d

163 he role of fibrocytes in chronic obstructive pulmonary disease (COPD) is unknown.

164 Dyspnoea in chronic obstructive pulmonary disease (COPD) may be linked to this reflex re

165 logic evidence suggested chronic obstructive pulmonary disease (COPD) might increase risk for abdomin

166 Chronic obstructive pulmonary disease (COPD) often coexists with cardiovascu

167 Some of the Chronic Obstructive Pulmonary Disease (COPD) patients engaged in exercise-ba

168 ; however, in asthma and chronic obstructive pulmonary disease (COPD) patients, this virus is a major

169 on risk in patients with chronic obstructive pulmonary disease (COPD) rely on a history of two or mor

170 Many individuals with chronic obstructive pulmonary disease (COPD) remain undiagnosed worldwide.

171 s for predicting risk of chronic obstructive pulmonary disease (COPD) require external validation in

172 rently, the diagnosis of chronic obstructive pulmonary disease (COPD) requires a ratio of forced expi

173 s after exacerbations of chronic obstructive pulmonary disease (COPD) requiring acute noninvasive ven

174 t the natural history of chronic obstructive pulmonary disease (COPD) that has developed from airway

175 atment for patients with chronic obstructive pulmonary disease (COPD) who have a high risk of exacerb

176 (n = 11) and those with chronic obstructive pulmonary disease (COPD) who were undergoing lung transp

177 Patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype

178 l treatment decisions in chronic obstructive pulmonary disease (COPD), a personalized approach to car

179 8) of patients exhibited chronic obstructive pulmonary disease (COPD), although only 19 had been prev

180 seases including asthma, chronic obstructive pulmonary disease (COPD), and critical illness.

181 aged 40 to 79 years have chronic obstructive pulmonary disease (COPD), and it is the third leading ca

182 diseases such as asthma, chronic obstructive pulmonary disease (COPD), and lung infections have criti

183 ovascular disease (CVD), chronic obstructive pulmonary disease (COPD), and lung-cancer mortality.

184 ARI), asthma, pneumonia, chronic obstructive pulmonary disease (COPD), and upper respiratory tract in

185 rway diseases, including chronic obstructive pulmonary disease (COPD), are associated with excessive

186 ing subphenotypes within chronic obstructive pulmonary disease (COPD), asthma, and other lung-related

187 ant in the management of chronic obstructive pulmonary disease (COPD), but can slightly increase the

188 airway in patients with chronic obstructive pulmonary disease (COPD), but their clinical and pathoph

189 atures of HIV-associated chronic obstructive pulmonary disease (COPD), but these changes have not bee

190 RATIONALE: Chronic obstructive pulmonary disease (COPD), in particular emphysema, is ch

191 RATIONALE: In chronic obstructive pulmonary disease (COPD), the benefits of pulmonary reha

192 lipidemia, hypertension, chronic obstructive pulmonary disease (COPD), ulcer history, use of proton p

193 lying CONDOR to eQTLs in chronic obstructive pulmonary disease (COPD), we found the global network "h

194 iduals and in those with chronic obstructive pulmonary disease (COPD), whereas shorter-term exposure

195 r-old man suffering from chronic obstructive pulmonary disease (COPD), who presented with non-massive

196 umor-enhancing effect of chronic obstructive pulmonary disease (COPD)-type airway inflammation.

197 therapeutic efficacy in chronic obstructive pulmonary disease (COPD).

198 g basis in patients with chronic obstructive pulmonary disease (COPD).

199 of FEV1 in patients with chronic obstructive pulmonary disease (COPD).

200 ne expression studies in chronic obstructive pulmonary disease (COPD).

201 nhaled corticosteroid in chronic obstructive pulmonary disease (COPD).

202 with worse outcomes than chronic obstructive pulmonary disease (COPD).

203 n studied in relation to chronic obstructive pulmonary disease (COPD).

204 atory diseases including chronic obstructive pulmonary disease (COPD).

205 nce are common in severe chronic obstructive pulmonary disease (COPD).

206 re in conditions such as chronic obstructive pulmonary disease (COPD).

207 ations are a hallmark of chronic obstructive pulmonary disease (COPD).

208 mphysema, a component of chronic obstructive pulmonary disease (COPD).

209 hyperpnoea in health and chronic obstructive pulmonary disease (COPD).

210 okers, and patients with chronic obstructive pulmonary disease (COPD).

211 ently as determinants of chronic obstructive pulmonary disease (COPD).

212 th cigarette smoking and chronic obstructive pulmonary disease (COPD).

213 robustly associated with chronic obstructive pulmonary disease (COPD).

214 tissue of patients with chronic obstructive pulmonary disease (COPD).

215 irway wall remodeling in chronic obstructive pulmonary disease (COPD).

216 acy in the management of chronic obstructive pulmonary disease (COPD).

217 ct conditions, including chronic obstructive pulmonary disease (COPD).

218 rsists in the airways in chronic obstructive pulmonary disease (COPD).

219 a key therapeutic aim in chronic obstructive pulmonary disease (COPD).

220 nhaled corticosteroid in chronic obstructive pulmonary disease (COPD).

221 with moderate to severe chronic obstructive pulmonary disease (COPD).

222 that was consistent with chronic obstructive pulmonary disease (COPD); these participants were more l

223 allergy (P = 0.045) and chronic obstructive pulmonary disease (COPD; P = 0.015).

224 er (LC; P=4.0 x 10(-4)), chronic obstructive pulmonary disease (COPD; P=9.3 x 10(-4)), peripheral art

225 eases such as asthma and chronic obstructive pulmonary diseases (COPD) affect more than one-half bill

226 (Genetic Epidemiology of Chronic Obstructive Pulmonary Disease [COPD]; non-Hispanic white and African

227 Genetic Epidemiology of Chronic Obstructive Pulmonary Disease (COPDGene) study to examine the role o

228 ary parameters to detect chronic obstructive pulmonary diseases (COPDs) such as asthma, bronchitis, o

229 dy mass index, diabetes, chronic obstructive pulmonary disease, coronary artery disease, peripheral a

230 This finding suggests that preexisting pulmonary disease could increase MERS-CoV receptor abund

231 elated acute lung injury), for assessment of pulmonary disease course and therapy, and in pulmonary t

232 ncluding specialists in infectious diseases, pulmonary diseases, critical care, and surgeons, anesthe

233 s and is associated with chronic obstructive pulmonary disease development and progression.

234 disease, heart failure, chronic obstructive pulmonary disease, diabetes mellitus, nitrate use, and e

235 n from two unrelated kindreds died of severe pulmonary disease during infancy following viral pneumon

236 cation, body mass index, chronic obstructive pulmonary disease, emphysema, personal history of cancer

237 eases such as asthma and chronic obstructive pulmonary disease, estimating physiologic impairment, an

238 portion of patients with chronic obstructive pulmonary disease, even after smoking cessation.

239 utcomes of patients with chronic obstructive pulmonary disease exacerbation treated with noninvasive

240 g patients with an acute chronic obstructive pulmonary disease exacerbation.

241 RATIONALE: Chronic obstructive pulmonary disease exacerbations are associated with dise

242 asthma exacerbations and chronic obstructive pulmonary disease exacerbations in adults.

243 armacologic treatment of chronic obstructive pulmonary disease has consistent beneficial and plausibl

244 c association studies in chronic obstructive pulmonary disease have primarily tested for association

245 entilatory efficiency in chronic obstructive pulmonary disease-heart failure overlap.

246 in children and adults, chronic obstructive pulmonary disease, hypertension, diabetes, obesity, perc

247 6.8 million) DALYs from chronic obstructive pulmonary disease in 2015.

248 left heart failure, and chronic obstructive pulmonary disease in not-operated patients.

249 mycobacteria (NTM) are an important cause of pulmonary disease in patients with cystic fibrosis (CF).

250 gement for patients with chronic obstructive pulmonary disease in primary care.

251 ed our understanding of the heterogeneity of pulmonary disease in smokers, they have not yet translat

252 ases, such as asthma and chronic obstructive pulmonary disease, include not only diagnostics (especia

253 lung, including asthma, chronic obstructive pulmonary disease, infections, and cancer.

254 criptional repertoire of chronic obstructive pulmonary disease, IPF, or normal histology lungs using

255 BACKGROUND AND Chronic obstructive pulmonary disease is increasing in prevalence and consti

256 tory viral pathogens on cystic fibrosis (CF) pulmonary disease is needed.

257 The pathogenesis of pulmonary diseases is often complex and characterized by

258 and predisposes them to chronic obstructive pulmonary disease later in life.

259 cerebrovascular disease, chronic obstructive pulmonary disease, lung cancer, and lower respiratory in

260 abnormalities documented in a wide array of pulmonary diseases may profoundly affect symptoms and pr

261 sthma cohort and a large chronic obstructive pulmonary disease metaanalysis cohort.

262 ofile but with increased chronic obstructive pulmonary disease, migraine, and affective disorders.

263 disease models including chronic obstructive pulmonary disease, multiple sclerosis, and stroke.

264 s to limit the impact of chronic obstructive pulmonary disease on everyday life of individuals and to

265 tic treatment and with no history of chronic pulmonary disease or use of asthma medication in the pas

266 .46; 95% CI, 0.36-0.59), chronic obstructive pulmonary disease (OR, 0.62; 95% CI, 0.52-0.75), diabete

267 .12-1.39; P < .001), and chronic obstructive pulmonary disease (OR, 1.26; 95% CI, 1.09-1.45; P = .002

268 terstitial lung disease, chronic obstructive pulmonary disease, or pulmonary arterial hypertension.

269 R 1.71; asthma: OR 1.56; chronic obstructive pulmonary disease: OR 1.65; cancer: OR 1.23; weak/failin

270 , 30-day readmission for chronic obstructive pulmonary disease (p = 0.83), or hospital length of stay

271 (older age, female sex, chronic obstructive pulmonary disease; P<0.05 for all), periprocedural major

272 ve recently gained attention in the field of pulmonary diseases, particularly in asthma and chronic o

273 aired ejection fraction, chronic obstructive pulmonary disease, peripheral vascular disease, or renal

274 , rheumatoid arthritis, Alzheimer's disease, pulmonary disease, pre-term delivery of low birth weight

275 Chronic obstructive pulmonary disease prevalence was higher among Puerto Ric

276 ept those with asthma or chronic obstructive pulmonary disease produced similar results.

277 ls from individuals with chronic obstructive pulmonary disease recapitulated features of the disease

278 nisms by which these events are regulated in pulmonary diseases remain poorly understood.

279 1beta responses occur in chronic obstructive pulmonary disease, respiratory infections, and neutrophi

280 ts with cystic fibrosis, chronic obstructive pulmonary disease, severe asthma, pre-existing pulmonary

281 ased from mild to severe chronic obstructive pulmonary disease severity.

282 eumonia (nine [5%]), and chronic obstructive pulmonary disease (six [3%]).

283 y due to respiratory and chronic obstructive pulmonary disease specifically were positive but impreci

284 tro cell based biological assays for various pulmonary diseases such as acute respiratory distress sy

285 ariation contributing to chronic obstructive pulmonary disease susceptibility.

286 our understanding of the pathophysiology of pulmonary diseases that arise either as a consequence of

287 susceptibility gene for chronic obstructive pulmonary disease, the physiologic role of this protease

288 of 13,893 patients with chronic obstructive pulmonary disease treated with noninvasive ventilation.

289 49 subjects from three cohorts without known pulmonary disease, we observed that pneumotypeSPT was as

290 ronic kidney disease and chronic obstructive pulmonary disease were important risk factors for SCD/VA

291 Second neoplasms, spinal disorders, and pulmonary disease were major contributors to the excess

292 erinflated patients with chronic obstructive pulmonary disease were randomized (1:1) to 7 (maximum 14

293 n mild-to-moderate stage chronic obstructive pulmonary disease where the rate of FEV1 decline is the

294 bowel disease) and lung (chronic obstructive pulmonary disease), where they contribute to IFN-gamma-m

295 PM10-2.5 is associated with pulmonary disease, which can lead to right ventricular (

296 uded 7,892 patients with chronic obstructive pulmonary disease who enrolled between 1981 and 2006.

297 Patients with chronic obstructive pulmonary disease, who had at least moderate airflow obs

298 ty of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy) trial was

299 he TIMP3 gene should be screened in familial pulmonary diseases with bronchiectasis, associated with

300 perammonaemia occurs in hepatic, cardiac and pulmonary diseases with increased muscle concentration o